First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Inclusion Criteria:

- Male, aged 22−55 years (both inclusive) at the time of signing informed consent

- Body mass index (BMI) between 25.0 and 34.9 kg/m^2 (both inclusive). Overweight should
be due to excess adipose tissue, as judged by the investigator

Exclusion Criteria:

- Any concomitant illness or disorder, which in the investigator's opinion might
jeopardise the subject's safety or compliance with the protocol

- Subjects aged above or equal to 40 years with an estimated 10-year atherosclerotic
cardiovascular disease (ASCVD according to ACC/AHA (American College of Cardiology
/American Heart Association) guideline) risk above or equal to 5%

- Male subjects who are not sexually abstinent or surgically sterilised (vasectomy) and
are sexually active with female partner(s) and who are not using a highly effective
method of contraception (such as condom with spermicide) combined with a highly
effective method of contraception for their non-pregnant female partner(s) (Pearl
Index below 1%, such as implants, injectables, oral contraceptives, intrauterine
devices, diaphragm or cervical cap+spermicide), and/or intend to donate sperm in the
period from screening (visit 1) until 3 months following administration of the
investigational medical product

- Use of prescription or non-prescription medicinal products including herbal products
and non-routine vitamins, within 2 weeks prior to screening, with the exception of
occasional use of acetaminophen, ibuprofen or acetylsalicylic acid